Haleon plc

HLN

GB00BMX86B70

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:50:26 20/09/2024 BST			5-day change	1st Jan Change
389.20 ^GBX	-0.46%		-0.84%	+21.19%

09-16	Haleon Picks PubMatic as Supply Partner for Media Buying	MT
09-13	Deutsche Bank cuts AstraZeneca to 'sell'	AN

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

August 01, 2024 at 07:00 am

Haleon plc provided earnings guidance for the fiscal year 2024. For the year, the company expects Organic revenue growth expected to be 4-6%. Organic operating profit growth high-single digit.

This compares with organic operating profit growth ahead of organic revenue growth previously shared at Haleon's First Quarter Trading Statement on 1 May 2024.

Latest news about Haleon plc

Haleon Picks PubMatic as Supply Partner for Media Buying	09-16	MT
Deutsche Bank cuts AstraZeneca to 'sell'	09-13	AN
Haleon Prices Offer of EUR750 Million, GBP300 Million Notes	09-12	MT
The mood is getting heavier, but Taylor Swift is keeping watch	09-11
3i Infrastructure cut; JPMorgan likes Rotork	09-11	AN
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary	09-04	CI
Haleon Seeks M&A Opportunities	09-03	CI
Haleon plc Presents at Barclays 17th Annual Global Consumer Staples Conference, Sep-03-2024 02:15 PM	09-03
Haleon Launches Erectile Dysfunction Treatment Eroxon in US	09-03	MT
Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription	09-03	CI
Futura Medical's Eroxon to be available in US from October	09-02	AN
AIM WINNERS & LOSERS: Futura Medica celebrates Eroxon launch in US	09-02	AN
Haleon Plans October Launch for Futura Medical's Erectile Dysfunction Gel in US	09-02	MT
Tate & Lyle picks former De Beers CFO to be its new CFO	08-13	AN
Tate & Lyle's New CFO to Join mid-September	08-13	MT
Market's Manic Monday morphs into Turnaround Tuesday	08-06
Goldman Sachs Downgrades Haleon to Neutral, Lifts PT	08-06	MT
Haleon adds former Tesco and M&S CFO Alan Stewart to board	08-06	AN
Berenberg Initiates Haleon at Buy With $11.44 Price Target	08-06	MT
Analyst recommendations: Amazon, Tesla, AMD, Kellanova, Nvidia...	08-06
Haleon plc Announces Board and Committees Appointments	08-06	CI
Liberum says sell Rio Tinto and Anglo American	08-06	AN
Global stocks tumble as risk-averse mood deepens	08-05	AN
European companies cut jobs as economy sputters	08-05	RE
Haleon plc: Portfolio of blockbusters	08-05

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).

Employees

25,408

Sector

Pharmaceuticals

Calendar

31/10/2024 - Q3 2024 Sales and Revenue Release - Trading Statement

More about the company